Followers | 827 |
Posts | 119518 |
Boards Moderated | 15 |
Alias Born | 09/05/2002 |
Saturday, February 18, 2017 4:09:14 PM
As a matter of policy, the FDA does not approve a product where there is an unresolved compliance issue anywhere in the product's supply chain, so the approval of 40mg Glatopa has to wait until the compliance issue is resolved. However, FDA policy does not automatically force the suspension of a marketed product just because it uses a facility with a compliance issue, so sales of 20mg Glatopa are not affected.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM